A 3-Part Study to Evaluate Safety, Tolerability, and Pharmacokinetics of MK-0873 Following Cumulative Patch and Repeated Max Area Applications in Healthy Subjects and Psoriasis Patients
Overview
- Phase
- Phase 1
- Intervention
- MK-0873 Patch
- Conditions
- Plaque Psoriasis
- Sponsor
- Merck Sharp & Dohme LLC
- Enrollment
- 42
- Primary Endpoint
- Number of Participants With an Adverse Event of Erythema in Part I of the Study
- Status
- Completed
- Last Updated
- 7 years ago
Overview
Brief Summary
This study will evaluate the incidence of erythema and other local cutaneous irritation after administration of MK-0873 by patch or cream formulation in healthy participants and participants with mild psoriasis. Part I and Part II in healthy participants will be initiated prior to Part III in psoriasis participants. The primary hypotheses of the study are: 1) that MK-0873 is safe and well tolerated in healthy participants and participants with psoriasis and 2) that the maximum plasma concentration of MK-0873 is <20 nM in healthy participants and participants with psoriasis.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Part I, II and III:
- •Female participants of reproductive potential must test negative for pregnancy and agree to use two acceptable methods of birth control;
- •In good general health;
- •Nonsmoker;
- •Part III only:
- •Has diagnosis of plaque-type psoriasis, and has lesions covering at least 3% of total body surface area;
Exclusion Criteria
- •Part I, II and III:
- •Has a history of stroke, chronic seizures or major neurological disease;
- •Has a history of cancer;
- •Is a nursing mother;
- •Part III only:
- •Has nonplaque forms of psoriasis;
- •Has current drug-induced psoriasis;
- •Has received phototherapy, systemic medications/treatments, or used topical medication that could affect psoriasis;
- •Has used any systemic immunosuppressants or biologics within the past 4 weeks.
Arms & Interventions
Panel A - MK-0873 5.1 mg
In Part I, healthy participants received skin patches containing nothing (plain patch), placebo, and various potencies of MK-0873 cream (0.05%, 0.5%, or 2%; yielding a dose of 5.1 mg of MK- 0873) once daily for 21 days.
Intervention: MK-0873 Patch
Panel A - MK-0873 5.1 mg
In Part I, healthy participants received skin patches containing nothing (plain patch), placebo, and various potencies of MK-0873 cream (0.05%, 0.5%, or 2%; yielding a dose of 5.1 mg of MK- 0873) once daily for 21 days.
Intervention: Placebo Patch
Panel A - MK-0873 5.1 mg
In Part I, healthy participants received skin patches containing nothing (plain patch), placebo, and various potencies of MK-0873 cream (0.05%, 0.5%, or 2%; yielding a dose of 5.1 mg of MK- 0873) once daily for 21 days.
Intervention: Plain patch
Panel A - Placebo
In Part I, healthy participants received skin patches containing nothing (plain patch) or placebo once daily for 10 days.
Intervention: Placebo Patch
Panel A - Placebo
In Part I, healthy participants received skin patches containing nothing (plain patch) or placebo once daily for 10 days.
Intervention: Plain patch
Panel B - MK-0873 25 mg
In Part II, healthy participants received skin application of 0.5% MK-0873 cream (yielding a dose of 25 mg of MK- 0873) twice daily for 10 days.
Intervention: MK-0873 Cream
Panel B - Placebo
In Part II, healthy participants received skin application of placebo cream twice daily for 10 days.
Intervention: Placebo Cream
Panel C - MK-0873 100 mg
In Part II, healthy participants received skin application of 2% MK-0873 cream (yielding a dose of 100 mg of MK-0873) once daily for 10 days.
Intervention: MK-0873 Cream
Panel C - Placebo
In Part II, healthy participants received skin application of placebo cream once daily for 10 days.
Intervention: Placebo Cream
Panel D - MK-0873 200 mg
In Part II, healthy participants received skin application of 2% MK-0873 (yielding a dose of 100 mg of MK-0873) twice daily for 10 days.
Intervention: MK-0873 Cream
Panel D - Placebo
In Part II, healthy participants received skin application of placebo cream twice daily for 10 days.
Intervention: Placebo Cream
Panel E and Extension - MK-0873 200 mg
In Part III, participants with mild psoriasis received skin application of 2% MK-0873 cream (yielding a dose of 100 mg of MK-0873) twice daily for up to 28 days.
Intervention: MK-0873 Cream
Panel E and Extension - Placebo
In Part III, participants with mild psoriasis received skin application of placebo cream twice daily for up to 28 days.
Intervention: Placebo Cream
Outcomes
Primary Outcomes
Number of Participants With an Adverse Event of Erythema in Part I of the Study
Time Frame: Up to Day 22 in Part 1
Following topical administration of MK-0873 or matching placebo patches once daily for 21 days, the number of participants with an adverse event of erythema was recorded. An adverse event is defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.
Number of Participants With an Adverse Event
Time Frame: Up to 14 days after last dose of study drug (up to Day 42)
An adverse event is defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.
Mean Maximum Plasma Concentration (Cmax) of MK-0873 Following Topical Administration for 10 Days
Time Frame: Day 11
Participant blood samples were collected on Day 11 to determine the Cmax of MK-0873 following topical administration in healthy participants and participants with psoriasis
Number of Participants Who Discontinued Study Medication Due to an Adverse Event
Time Frame: Up to Day 28
An adverse event is defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.